{
    "clinical_study": {
        "@rank": "68805", 
        "arm_group": {
            "arm_group_label": "Diagnosis (FDG PET/CT and PET/MRI)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies positron emission tomography (PET)/computed tomography (CT) or\n      PET/magnetic resonance imaging (MRI) in measuring tumors in patients undergoing clinical\n      imaging or with newly diagnosed breast cancer. New diagnostic procedures, such as PET/CT or\n      PET/MRI, may be more effective than MRI alone in measuring tumors in patients undergoing\n      clinical imaging or with newly diagnosed breast cancer."
        }, 
        "brief_title": "PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer", 
        "condition": [
            "Breast Cancer", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To improve visualization of tumors by developing better image reconstruction and\n      correction methods.\n\n      II. To revise the positioning devices and, if necessary, scanner table to fit a wider size\n      range of women.\n\n      OUTLINE:\n\n      Patients undergo clinical fludeoxyglucose F-18 (FDG)-PET/CT followed by prone breast PET/CT\n      and/or prone breast PET/MRI with or without gadopentetate dimeglumine (DTPA)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  [Cohorts 1 and 2] Female patients who are referred by their physician to have a\n             clinical PET/CT\n\n          -  [Cohort 3] Patients referred for clinical breast dynamic contrast-enhanced (DCE)-MRI\n             for recently diagnosed breast cancer\n\n          -  Normal kidney function for subjects that will receive magnetic resonance (MR)\n             contrast agent as part of their clinical imaging\n\n          -  For subjects for whom MR contrast agent is to be administered, University Hospitals\n             (UH) policy 8.17.26 will be applied\n\n               -  The following guidelines will be followed when a patient or patient\n                  representative responds \"yes\" to questions on the MRI history sheet 'Are you on\n                  dialysis, history of kidney failure, end stage renal disease, chronic liver\n                  disease, or are you a peri-liver transplant patient':\n\n                    -  The patient must have a serum creatinine value available within three (3)\n                       weeks prior to the injection of gadolinium\n\n                    -  Calculate an estimated glomerular filtration rate (eGFR) based on serum\n                       creatinine; if the eGFR is less than 30 the attending radiologist must\n                       discuss the risks and benefits of administering gadolinium with the\n                       referring physician and patient; the collective judgment of the patient,\n                       radiologist and referring physician must be in agreement to proceed with\n                       the injection of gadolinium\n\n                    -  Calculated eGFR in range of 31-59 requires the judgment of the attending\n                       radiologist whether to discuss gadolinium administration with referring\n                       physician and patient or whether to directly use or hold the contrast agent\n\n                    -  If an eGFR is greater than 60, gadolinium may be administered without\n                       further physician or patient discussion\n\n                    -  Gadolinium administration is limited to single dose at 0.1mmol/kg; Omniscan\n                       should not be used\n\n                    -  Technologist will document radiologist decision to administer gadolinium on\n                       the MRI history sheet; radiologist will document decision and consultation\n                       with the referring physician and patient in the MRI report\n\n                    -  PERITONEAL DIALYSIS PATIENTS:\n\n                         -  No gadolinium will be administered unless the patient has been\n                            scheduled for hemodialysis within 24 hours following the injection of\n                            gadolinium; technologist will determine eGFR and follow above\n                            guidelines; dialysis will be scheduled by the referring physician\n\n                    -  HEMODIALYSIS PATIENTS:\n\n                         -  No gadolinium will be administered unless the patient has been\n                            scheduled for hemodialysis within 24 hours following the injection of\n                            gadolinium; no determination of eGFR is necessary; radiologist will\n                            assume eGFR less than 30 and follow above guidelines; dialysis will be\n                            scheduled by the referring physician\n\n          -  Ability to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Subjects who do not meet all of the above inclusion criteria\n\n          -  Subjects unwilling or unable to sign the informed consent form\n\n          -  Subjects who are cognitively impaired and thus unable to give informed consent\n\n          -  Subjects unable to undergo MR scanning due to exclusion via University Hospitals Case\n             Medical Center (UHCMC) MR restrictions (e.g. certain implanted metallic or electronic\n             devices)\n\n          -  Subjects who are pregnant\n\n          -  Subjects that are too large to fit comfortably into the PET/MR on the breast coil;\n             for cohort 1 only we will accept a maximum of 10 subjects that are too large for the\n             PET/MRI to acquire a prone PET/CT but without the paired PET/MR"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892540", 
            "org_study_id": "CASE15112", 
            "secondary_id": [
                "NCI-2013-00938", 
                "PMI TECH 12-050"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnosis (FDG PET/CT and PET/MRI)", 
                "description": "Undergo PET/CT", 
                "intervention_name": "positron emission tomography/computed tomography", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnosis (FDG PET/CT and PET/MRI)", 
                "description": "Undergo FDG-PET/CT", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "18FDG", 
                    "FDG"
                ]
            }, 
            {
                "arm_group_label": "Diagnosis (FDG PET/CT and PET/MRI)", 
                "description": "Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging", 
                "intervention_name": "PET/MRI", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Diagnosis (FDG PET/CT and PET/MRI)", 
                "description": "Undergo DTPA-PET/MRI", 
                "intervention_name": "gadopentetate dimeglumine", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "gadolinium DTPA", 
                    "Gd-DTPA", 
                    "Magnevist", 
                    "MultiHance"
                ]
            }, 
            {
                "arm_group_label": "Diagnosis (FDG PET/CT and PET/MRI)", 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "email": "donna.plecha@uhhospitals.org", 
                "last_name": "Donna Plecha", 
                "phone": "216-844-5252"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106-5065"
                }, 
                "name": "Case Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Donna Plecha", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Positron Mammographic Imaging (PMI)", 
        "overall_official": {
            "affiliation": "Case Comprehensive Cancer Center", 
            "last_name": "Donna Plecha, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Uptake and attenuation correction of PET/MRI and PET/CT will be examined by comparing SUVs of the two methods. The proportions of subjects with SUV of the PET/MR within 5%, 10%, and 20% of the SUV from PET/CT will be estimated with exact 95% confidence intervals.", 
                "measure": "Attenuation correction for PET/MRI, assessed using standard uptake values (SUVs) (Cohorts I & II)", 
                "safety_issue": "No", 
                "time_frame": "1 yr from study start"
            }, 
            {
                "description": "Uptake and attenuation correction of PET/MRI and PET/CT will be examined by comparing SUVs of the two methods. The proportions of subjects with SUV of the PET/MR within 5%, 10%, and 20% of the SUV from PET/CT will be estimated with exact 95% confidence intervals.", 
                "measure": "Attenuation correction for PET/CT, assessed using SUVs (Cohorts I & II)", 
                "safety_issue": "No", 
                "time_frame": "1 yr from study start"
            }, 
            {
                "description": "McNemar's test or a generalized estimating equations logistic regression model with patient as the cluster used to compare specificity rates of the new technology versus current technology (MRI alone), restricting analysis to true negative lesions. Positive predictive values (PPVs) calculated from estimates of sensitivity, specificity, and prevalence, and compared between methods using bootstrap confidence intervals for the difference in PPVs. Receiver operating curves (ROCs) also estimated and the areas under the ROC curves compared between methods using methods of Delong et al.", 
                "measure": "Specificity rates of fused FDG-PET/MRI (Cohort III)", 
                "safety_issue": "No", 
                "time_frame": "1 yr from study start"
            }, 
            {
                "description": "McNemar's test or a generalized estimating equations logistic regression model with patient as the cluster used to compare sensitivity of methods, restricting analysis to true negative lesions. PPVs calculated from estimates of sensitivity, specificity, and prevalence, and compared between methods using bootstrap confidence intervals for the difference in PPVs. ROCs also estimated and the areas under the ROC curves compared between methods using methods of Delong et al.", 
                "measure": "Sensitivity of PET/CT and PET/MRI (Cohort III)", 
                "safety_issue": "No", 
                "time_frame": "1 yr from study start"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}